1. Home
  2. Category
  3. Treatment Types

Clinical Trials

Article

Backing and Forthing: The Process of Decision Making by Women Considering Participation in a Breast Cancer Prevention Trial

Karen Moore Schaefer
Elisabeth Ladd
Mary Ann Gergits
Lorraine Gyauch
ONF 2001, 703-709 DOI:
Purpose/Objectives: To describe the process of decision making by women considering participation in a breast cancer prevention trial (BCPT). Design: Qualitative. Setting/Sample: Twenty-six women considering participation in a BCPT in the Northeastern United States. Methods: Women were interviewed...
0
No votes yet
Read this Article
Commentary

Disparities in Hispanic Care

Marjorie Petty
CJON 2019, 23(3), 235 DOI: 10.1188/19.CJON.235
Attendees at a 2019 ONS Congress session about disparities in clinical trials seemed to be aware that African Americans are underrepresented. But what about Hispanic patients with cancer? I sensed that some of my colleagues had not considered Hispanic recruitment before and were surprised to learn...
0
No votes yet
Read this Article
CNE Article

CAR T-Cell Therapy: Update on the State of the Science

Misty Lamprecht
Colleen Dansereau
CJON 2019, 23(2), 6-12 DOI: 10.1188/19.CJON.S1.6-12
Background: Chimeric antigen receptor (CAR) T-cell therapy leverages the power of the patient’s own immune system by serving as a bridge to connect genetically modified T cells to the surface antigens of tumor cells based on targeted ligands. Clinical trials have demonstrated compelling overall...
5
Average: 5 (1 vote)
Read this Article
Communities

Cancer Clinical Trials: Improving Awareness and Access for Minority and Medically Underserved Communities

Melissa Beauchemin
Grace Hillyer
Diane St. Germain
CJON 2019, 23(2), 220-223 DOI: 10.1188/19.CJON.220-223
Cancer clinical trials offer patients an opportunity to receive new and innovative treatment, as well as contribute to the future of cancer care. Enrollment onto clinical trials also may lead to better care and outcomes; however, few adult patients with cancer and even fewer ethnic and racial...
0
No votes yet
Read this Article
Online Exclusive Article

Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer

Anne Rodrigues Ferreira
Eliete Farias Azevedo
ONF 2019, 46(1), E38-E47 DOI: 10.1188/19.ONF.E38-E47
Problem Identification: Subcutaneous (SC) formulations for monoclonal antibodies (mAbs) must be evaluated for efficacy and safety in comparison with preexisting IV formulations to identify potential benefits and risks. Literature Search: This is a systematic review of clinical trials. MEDLINE®/...
0
No votes yet
Read this Article

Related e-Books

View More

Questions, Concerns or Requests

We're just a click away for assistance.